APVO vs. MBRX, ERNA, MNPR, GRTX, ABVC, VAXX, AEZS, OGEN, CMMB, and ATHE
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Moleculin Biotech (MBRX), Eterna Therapeutics (ERNA), Monopar Therapeutics (MNPR), Galera Therapeutics (GRTX), ABVC BioPharma (ABVC), Vaxxinity (VAXX), Aeterna Zentaris (AEZS), Oragenics (OGEN), Chemomab Therapeutics (CMMB), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, Aptevo Therapeutics had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 2 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 1.25 beat Aptevo Therapeutics' score of 1.13 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Moleculin Biotech has a consensus target price of $35.00, suggesting a potential upside of 677.78%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Aptevo Therapeutics.
Moleculin Biotech received 29 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 53.16% of users gave Moleculin Biotech an outperform vote while only 52.66% of users gave Aptevo Therapeutics an outperform vote.
Aptevo Therapeutics has higher revenue and earnings than Moleculin Biotech.
8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 0.3% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 6.7% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Moleculin Biotech's return on equity of -87.19% beat Aptevo Therapeutics' return on equity.
Aptevo Therapeutics has a beta of 5.13, suggesting that its share price is 413% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Summary
Moleculin Biotech beats Aptevo Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
